Adverse effects: pain on injection (solution deposition), Heft-Parker VAS 0-170 mm · patients treated with subcutaneous heparin injections
1 finding from 1 review
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · patients treated with subcutaneous heparin injections
1 finding from 1 review
Bruise size 48 hours after injection (mm/mm2) · patients treated with subcutaneous heparin injections
1 finding from 1 review
Bruise size ‐ 60 hours after injection (mm2) · patients treated with subcutaneous heparin injections
1 finding from 1 review
Bruise size ‐ 72 hours after injection (mm2) · patients treated with subcutaneous heparin injections
1 finding from 1 review
Bruise incidence ‐ 48 hours after injection · patients treated with subcutaneous heparin injections
Slow may leads to lower bruise incidence ‐ 48 hours after injection compared with fast subcutaneous heparin injection (low certainty).
2 findings from 1 review
Improvement in lower limb perfusion: ABI · people with critical limb ischaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Improvement in lower limb perfusion: TcO₂ reading in mmHg · people with critical limb ischaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Deep vein thrombosis · prevention of venous thromboembolism in patients with lower‐limb immobilization
Low molecular weight heparin probably leads to lower deep venous thrombosis compared with no prophylaxis or placebo (moderate certainty).
1 finding from 1 review
Pulmonary embolism · prevention of venous thromboembolism in patients with lower‐limb immobilization
Low molecular weight heparin showed no clear difference in pulmonary embolism compared with no prophylaxis or placebo (low certainty).
1 finding from 1 review
Symptomatic venous thromboembolism · prevention of venous thromboembolism in patients with lower‐limb immobilization
Low molecular weight heparin may leads to lower symptomatic venous thromboembolism compared with no prophylaxis or placebo (low certainty).
1 finding from 1 review
Mortality due to pulmonary embolism · prevention of venous thromboembolism in patients with lower‐limb immobilization
1 finding from 1 review
Mortality due to other causes · prevention of venous thromboembolism in patients with lower‐limb immobilization
Low molecular weight heparin showed no clear difference in mortality due to other causes compared with no prophylaxis or placebo (low certainty).
1 finding from 1 review
Adverse outcomes · prevention of venous thromboembolism in patients with lower‐limb immobilization
Low molecular weight heparin showed no clear difference in adverse outcomes compared with no prophylaxis or placebo (low certainty).
1 finding from 1 review
Improvement in lower limb perfusion: ABI · people with critical limb ischaemia
1 finding from 1 review
Improvement in lower limb perfusion: TcO₂ reading in mmHg · people with critical limb ischaemia
1 finding from 1 review
Improvement in lower limb perfusion: ABI · people with critical limb ischaemia
It is very uncertain whether IM injection changes improvement in lower limb perfusion: number of participants with… compared with IA injection (very low certainty).
1 finding from 1 review
Improvement in lower limb perfusion: number of participants with improved TcO₂ reading · people with critical limb ischaemia
It is very uncertain whether IM injection changes improvement in lower limb perfusion: number of participants with… compared with IA injection (very low certainty).
1 finding from 1 review
Improvement in lower limb perfusion: ABI · people with critical limb ischaemia
BM‐MNCs showed no clear difference in improvement in lower limb perfusion: number of participants with… compared with mPBSCs (low certainty).
1 finding from 1 review
Improvement in lower limb perfusion: TcO₂ reading in mmHg · people with critical limb ischaemia
1 finding from 1 review